Akebia Therapeutics IncQ) expected to post a loss of 2 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
Akebia Therapeutics IncQ) is anticipated to report a loss of 2 cents per share, with a projected 8.2% increase in quarterly revenue to $47.237 million for the period ending June 30, 2025. Analysts maintain a "strong buy" rating, with a median 12-month price target of $7.00, reflecting a 46.3% upside from the last closing price of $3.76. The earnings estimates have remained unchanged over the past three months, with previous quarterly performances showing mixed results against estimates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments